These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25616604)

  • 1. The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up.
    Petzold A
    J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1388-90. PubMed ID: 25616604
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilaments as biomarkers in multiple sclerosis.
    Teunissen CE; Khalil M
    Mult Scler; 2012 May; 18(5):552-6. PubMed ID: 22492131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilaments and 10-year follow-up in multiple sclerosis.
    Bhan A; Jacobsen C; Myhr KM; Dalen I; Lode K; Farbu E
    Mult Scler; 2018 Sep; 24(10):1301-1307. PubMed ID: 30066611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of CSF neurofilament light and heavy chain protein in MS.
    Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L
    Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis.
    Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F
    Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis.
    Trentini A; Comabella M; Tintoré M; Koel-Simmelink MJ; Killestein J; Roos B; Rovira A; Korth C; Ottis P; Blankenstein MA; Montalban X; Bellini T; Teunissen CE
    J Neurol; 2014 Dec; 261(12):2338-43. PubMed ID: 25228004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.
    Lycke JN; Karlsson JE; Andersen O; Rosengren LE
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):402-4. PubMed ID: 9527161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
    Albanese M; Zagaglia S; Landi D; Boffa L; Nicoletti CG; Marciani MG; Mandolesi G; Marfia GA; Buttari F; Mori F; Centonze D
    J Neuroinflammation; 2016 Feb; 13():36. PubMed ID: 26863878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain as an indicator of exacerbation prior to clinical symptoms in multiple sclerosis.
    Edwards KR; Garten L; Button J; O'Connor J; Kamath V; Frazier C
    Mult Scler Relat Disord; 2019 Jun; 31():59-61. PubMed ID: 30927733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
    Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J
    Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis.
    Zetterberg H
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():15-17. PubMed ID: 29068494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein.
    Kuhle J; Regeniter A; Leppert D; Mehling M; Kappos L; Lindberg RL; Petzold A
    J Neuroimmunol; 2010 Mar; 220(1-2):114-9. PubMed ID: 20117845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.
    Petzold A; Eikelenboom MJ; Keir G; Grant D; Lazeron RH; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G
    J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):206-11. PubMed ID: 15654034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis.
    Fialová L; Bartos A; Svarcová J; Zimova D; Kotoucova J; Malbohan I
    J Neuroimmunol; 2013 Sep; 262(1-2):113-20. PubMed ID: 23870535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis.
    Lim ET; Sellebjerg F; Jensen CV; Altmann DR; Grant D; Keir G; Thompson EJ; Giovannoni G
    Mult Scler; 2005 Oct; 11(5):532-6. PubMed ID: 16193890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are neurofilaments valuable biomarkers for long-term disease prognostication in MS?
    Khalil M
    Mult Scler; 2018 Sep; 24(10):1270-1271. PubMed ID: 30066596
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple sclerosis cerebrospinal fluid biomarkers.
    Giovannoni G
    Dis Markers; 2006; 22(4):187-96. PubMed ID: 17124340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis.
    Kuhle J; Leppert D; Petzold A; Regeniter A; Schindler C; Mehling M; Anthony DC; Kappos L; Lindberg RL
    Neurology; 2011 Apr; 76(14):1206-13. PubMed ID: 21346223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofilament light as a prognostic marker in multiple sclerosis.
    Salzer J; Svenningsson A; Sundström P
    Mult Scler; 2010 Mar; 16(3):287-92. PubMed ID: 20086018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.